AMRN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Amarin's gross profit for the three months ended in Dec. 2024 was $-9.6 Mil. Amarin's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $81.4 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Amarin's gross profit for the three months ended in Dec. 2024 was $-9.6 Mil. Amarin's Revenue for the three months ended in Dec. 2024 was $62.3 Mil. Therefore, Amarin's Gross Margin % for the quarter that ended in Dec. 2024 was -15.35%.
Amarin had a gross margin of -15.35% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
During the past 13 years, the highest Gross Margin % of Amarin was 79.20%. The lowest was 35.60%. And the median was 74.38%.
Warning Sign:
Amarin Corp PLC gross margin has been in long-term decline. The average rate of decline per year is -13.9%.
The historical data trend for Amarin's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amarin Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Gross Profit | Get a 7-Day Free Trial |
![]() |
![]() |
482.62 | 461.86 | 242.48 | 165.54 | 81.38 |
Amarin Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Gross Profit | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
45.12 | 31.90 | 42.77 | 16.28 | -9.57 |
For the Drug Manufacturers - General subindustry, Amarin's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Amarin's Gross Profit distribution charts can be found below:
* The bar in red indicates where Amarin's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Amarin's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as
Gross Profit (A: Dec. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 228.614 | - | 147.232 | |
= | 81.4 |
Amarin's Gross Profit for the quarter that ended in Dec. 2024 is calculated as
Gross Profit (Q: Dec. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 62.306 | - | 71.873 | |
= | -9.6 |
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $81.4 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Amarin's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as
Gross Margin % (Q: Dec. 2024 ) | = | Gross Profit (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | -9.6 | / | 62.306 | |
= | -15.35 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Amarin (NAS:AMRN) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Amarin had a gross margin of -15.35% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
Thank you for viewing the detailed overview of Amarin's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Aaron Berg | officer: EVP, President US | C/O AMARIN PHARMA, INC., 1430 ROUTE 206, BEDMINSTER NJ 07921 |
Patrick Holt | director, officer: See Remarks | C/O AMARIN CORPORATION, SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Steven B Ketchum | officer: Chief Scientific Officer | 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303 |
Oliver O'connor | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Paul Cohen | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Diane E. Sullivan | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Louis Iii Sterling | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Keith Horn | director | 204 STATE ROUTE 17B, P.O. BOX 5013, C/O MONTICELLO CASINO AND RACEWAY, MONTICELLO NY 12701 |
Patrice Eadon Bonfiglio | director | 488 HAVILAND ROAD, STAMFORD CT 06903 |
Mark Dipaolo | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Thomas Charles Reilly | officer: SVP and CFO | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902 |
Karim Mikhail | director, officer: President and CEO | C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807 |
Olsen Per Wold | director | C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Murray Stewart | director | C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3 |
From GuruFocus
By Marketwired • 07-17-2024
By Marketwired • 10-30-2024
By Marketwired • 12-16-2024
By GuruFocus News • 10-09-2024
By Marketwired • 05-06-2024
By Marketwired • 03-12-2025
By GuruFocus News • 11-21-2024
By GuruFocus News • 03-13-2025
By Marketwired • 07-17-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.